The Situation
Launch of 1st treatment for spinal muscular atrophy on fast-track approval pathway in US. Payors had very little awareness of disease & no reimbursement process
The Solution
EVERSANA educated payors on disease, patient journey & treatment value .
Identified access barriers such as complicated reimbursement pathway and developed tools to facilitate.
The Results
Coverage to FDA label was achieved with 90% of payors within 3 months of launch.